Conditional loss of <em>Nmp4</em> in mesenchymal stem progenitor cells enhances PTH-induced bone formation

Atkinson, Emily G.<sup>1</sup>; Adaway, Michele<sup>1</sup>; Horan, Daniel J.<sup>1,2</sup>; Korff, Crystal<sup>3</sup>; Klunk, Angela<sup>1</sup>; Orr, Ashley L.<sup>1</sup>; Ratz, Katherine<sup>1</sup>; Bellido, Teresita<sup>4,5</sup>; Plotkin, Lilian I.<sup>1,6</sup>; Robling, Alexander G.<sup>1,2,6</sup>; Bidwell, Joseph P.<sup>1,6</sup>

Affiliations

¹Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine (IUSM), Indianapolis, IN, USA

²Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN, USA

³Department of Medical and Molecular Genetics, Indiana University School of Medicine (IUSM), Indianapolis, IN, USA

⁴Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA

⁵Central Arkansas Veterans Healthcare System, Little Rock, AR, USA

⁶Indiana Center for Musculoskeletal Health, Indiana University School of Medicine (IUSM), Indianapolis, IN, USA

Abstract and keywords

Activation of bone anabolic pathways is a fruitful approach for treating severe osteoporosis, yet FDA-approved osteoanabolics, eg, parathyroid hormone (PTH), have limited efficacy. Improving their potency is a promising strategy for maximizing bone anabolic output. Nmp4 (Nuclear Matrix Protein 4) global knockout mice exhibit enhanced PTH-induced increases in trabecular bone but display no overt baseline skeletal phenotype. Nmp4 is expressed in all tissues; therefore, to determine which cell type is responsible for driving the beneficial effects of Nmp4 inhibition, we conditionally removed this gene from cells at distinct stages of osteogenic differentiation. Nmp4-floxed (Nmp4^fl/fl) mice were crossed with mice bearing one of three Cre drivers including (i) Prx1Cre⁺+ to remove Nmp4 from mesenchymal stem/progenitor cells (MSPCs) in long bones; (ii) BglapCre⁺+ targeting mature osteoblasts, and (iii) Dmp1Cre⁺+ to disable Nmp4 in osteocytes. Virgin female Cre+ and Cre− mice (10 weeks of age) were sorted into cohorts by weight and genotype. Mice were administered daily injections of either human PTH 1-34 at 30 μg/kg or vehicle for 4 weeks or 7 weeks. Skeletal response was assessed using dual-energy X-ray absorptiometry, micro-computed tomography, bone histomorphometry, and serum analysis for remodeling markers. Nmp4^fl/fl;Prx1Cre⁺+ mice virtually phenocopied the global Nmp4^−/− skeleton in the femur, ie, a mild baseline phenotype but significantly enhanced PTH-induced increase in femur trabecular bone volume/total volume (BV/TV) compared with their Nmp4^fl/fl;Prx1Cre⁺⁻ controls. This was not observed in the spine, where Prrx1 is not expressed. Heightened response to PTH was coincident with enhanced bone formation. Conditional loss of Nmp4 from the mature osteoblasts (Nmp4^fl/fl;BglapCre⁺+) failed to increase BV/TV or enhance PTH response. However, conditional disabling of Nmp4 in osteocytes (Nmp4^fl/fl;Dmp1Cre⁺+) increased BV/TV without boosting response to hormone under our experimental regimen. We conclude that Nmp4^−/− Prx1-expressing MSPCs drive the improved response to PTH therapy and that this gene has stage-specific effects on osteoanabolism.

Keywords: BONE ANABOLISM; OSTEOANABOLICS; OSTEOPOROSIS; TERIPARATIDE; BONE ANABOLISM; OSTEOANABOLICS; OSTEOPOROSIS; TERIPARATIDE

Links

DOI: 10.1002/jbmr.4732

PubMed: 36321253

WoS: 000888236000001

History

Received: 2022-06-27

Revised: 222-10-12

Accepted: 2022-10-29

Cited Works (23)

Year	Entry
2010	Dallas SL, Bonewald LF. Dynamics of the transition from osteoblast to osteocyte. Annals NY Acad Sci. March 2010;1192(1):437-443.
2020	Ström O, Lauppe R, Ljunggren Ö, Spångéus A, Ortsäter G, O’Kelly J, Åkesson K. Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporos Int. August 2020;31(8):1525-1533.
2014	Mizoguchi T, Pinho S, Ahmed J, Kunisaki Y, Hanoun M, Mendelson A, Ono N, Kronenberg HM, Frenette PS. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Dev Cell. May 12, 2014;29(3):340-349.
2002	Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. November 15, 2002;277(46):44005-44012.
2012	Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. January 2012;50(1):209-217.
2018	Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. January 20, 2018;391(10117):230-240.
2019	Yang M, Arai A, Udagawa N, Zhao L, Nishida D, Murakami K, Hiraga T, Takao-Kawabata R, Matsuo K, Komori T, Kobayashi Y, Takahashi N, Isogai Y, Ishizuya T, Yamaguchi A, Mizoguchi T. Parathyroid hormone shifts cell fate of a leptin receptor‐marked stromal population from adipogenic to osteoblastic lineage. J Bone Miner Res. October 2019;34(10):1952-1963.
2017	Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. March 2017;96:29-37.
2002	Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet. May 18, 2002;359(9319):1761-1767.
2021	Balani DH, Trinh S, Xu M, Kronenberg HM. Sclerostin antibody administration increases the numbers of Sox9creER+ skeletal precursors and their progeny. J Bone Miner Res. April 2021;36(4):757-767.
1996	Ajubi NE, Klein-Nulend J, Nijweide PJ, Vrijheid-Lammers T, Alblas MJ, Burger EH. Pulsating fluid flow increases prostaglandin production by cultured chicken osteocytes: a cytoskeleton-dependent process. Biochem Biophys Res Commun. August 5, 1996;225(1):62-68.
2014	Schaffler MB, Cheung W-Y, Majeska R, Kennedy O. Osteocytes: master orchestrators of bone. Calcif Tiss Int. January 2014;94(1):5-24.
2020	Hongo H, Hasegawa T, Saito M, Tsuboi K, Yamamoto T, Sasaki M, Abe M, de Freitas PHL, Yurimoto H, Udagawa N, Li M, Amizuka N. Osteocytic osteolysis in PTH-treated wild-type and Rankl^−/− mice examined by transmission electron microscopy, atomic force microscopy, and isotope microscopy. J Histochem Cytochem. October 2020;68(10):651-668.
1999	Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. August 1999;104(4):439-446.
1998	Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. May 1998;13(5):793-802.
2012	Kim SW, Pajevic PD, Selig M, Barry KJ, Yang J-Y, Shin CS, Baek W-Y, Kim J-E, Kronenberg HM. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res. October 2012;27(10):2075-2084.
2017	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427.
2016	Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. NEJM. October 20, 2016;375(16):1532-1543.
2020	Conley RB, Adib G, Adler RA, Åkesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman‐Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kužma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, Napoli N, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res. January 2020;35(1):36-52.
2017	Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T, Balani DH, Ominsky MS, Ke HZ, Kronenberg HM, Wein MN. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J Bone Miner Res. May 2017;32(5):892-901.
2013	Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. February 2013;19(2):179-192.
2013	Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. January 2013;28(1):2-17.
2000	Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. April 2000;21(2):115-137.